.png){kind=icon}
.png){kind=icon}
Return
Effectiveness and safety of ustekinumab in pediatric Crohn's disease: Results of the REALITI study
.png){kind=icon}
PRE
AI
S
J
S
R
K
A
R
K
K
K
E
K
Z
L
R
S
DOI：10.1002/jpn3.70372.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
Objectives Few approved treatments exist for children with Crohn's disease (CD). The REALITI study retrospectively assessed the effectiveness and safety of ustekinumab in real-world clinical settings for children with CD. Methods Data were collected from the prospective ImproveCareNow (ICN) registry for pediatric patients (>= 2 to <18 years old) and young adult patients (>= 18 to <26 years old), regardless of baseline CD severity. Additional analyses were conducted for a subset of patients who had moderately-to-severely active CD (short pediatric CD activity index [sPCDAI] >= 30). Key Week-52 endpoints included clinical remission (sPCDAI <= 10) and corticosteroid-free (CF) clinical remission. Safety events of interest were assessed at Week 52. Results Overall, 479 patients with CD were treated with ustekinumab, 348 pediatric patients and 131 young adults; most were biologic-exposed (pediatric, 98.9%; young adult, 95.4%). At Week 52 (observed case; excluding patients without Week 52 data), clinical remission was achieved by 47.3% (125/264) of pediatric patients and 44.8% (39/87) of young adults, and CF clinical remission by 41.3% (109/264) and 39.1% (34/87), respectively. At Week 52 (observed case), among patients with moderately-to-severely active CD, clinical remission was achieved by 36.9% (41/111) of pediatric patients and 34.3% (12/35) of young adults, and CF clinical remission by 31.5% (35/111) and 28.6% (10/35), respectively. Ustekinumab was well tolerated, with no new safety signals identified. Conclusions In the REALITI study of real-world data from the ICN registry, the effectiveness and safety of ustekinumab treatment through 52 weeks were similar in pediatric and young adult patients with CD.
Keywords:
biologic product
children
inflammatory bowel disease
real-world
registries
Journal
IF:
2.6
Papers:
250
Citations:
1.4W
Organization
Cited Papers